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Abstract
Background and Purpose
Previous studies indicate that prostaglandin EP2 receptors (EP2Rs) selectively
couple to adenylyl cyclase type 2 (AC2) in non-lipid raft domains of airway smooth
muscle (ASM) cells, where they regulate specific cAMP-dependent responses. The
goal of the present study was to identify the cellular microdomains where EP2Rs
stimulate cAMP production.
Experimental Approach
FRET-based cAMP biosensors were targeted to different subcellular locations of
primary human ASM cells. The Epac2-camps biosensor, which expresses
throughout the cell, was used to measure bulk cytoplasmic responses. Epac2MyrPalm and Epac2-CAAX were used to measure responses associated with lipid
raft and non-raft regions of the plasma membrane, respectively. Epac2-NLS was
used to monitor responses at the nucleus.
Key Results
Activation of AC with forskolin or β2-adrenergic receptors (β2ARs) with isoproterenol
increased cAMP in all subcellular locations. Activation of EP2Rs with butaprost
produced cAMP responses that were most readily detected by the non-raft and
nuclear sensors, but only weakly detected by the cytosolic sensor and not detected
at all by the lipid raft sensor. Exposure to rolipram, a phosphodiesterase type 4
(PDE4) inhibitor, unmasked the ability of EP2Rs to increase cAMP levels associated
with lipid raft domains. Overexpression of AC2 selectively increased EP2R-stimulated
production of cAMP in non-raft membrane domains.
Conclusions and Implications
EP2R activation of AC2 leads to cAMP production in non-raft and nuclear
compartments of human ASMs, while β2AR signaling is broadly detected across
microdomains. Activity of PDE4 appears to play a role in maintaining the integrity of
compartmentalized EP2R responses in these cells.
Non-standard Abbreviations
AKAP – A kinase anchoring protein
This article is protected by copyright. All rights reserved.

AC2 – adenylyl cyclase type 2
AC6 – adenylyl cyclase type 6
ASM – airway smooth muscle
β2AR – beta-2 adrenergic receptor
But – butaprost
CREB – cAMP response element binding protein
Epac2-camps – exchange protein activated by cAMP type 2 based cAMP biosensor
Epac2-CAAX – Epac2-camps biosensor with a prenylation targeting sequence
Epac2-MyrPalm – Epac2-camps biosensor with an acylation targeting sequence
Epac2-NLS – Epac2-camps biosensor with a nuclear localization signal
EP2R – EP2 prostaglandin receptor
FSK – forskolin
IL-6 – interleukin 6
IBMX – isobutylmethylxanthine
Iso – isoproterenol
PDE – phosphodiesterase
PDE4 – phosphodiesterase type 4
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Introduction
Stimulation of cAMP production regulates bronchomotor tone by causing relaxation
of airway smooth muscle (ASM) cells (Pelaia et al., 2008; Noble et al., 2014).
Furthermore, disruption of cAMP signaling is believed to contribute to hyperresponsiveness to contractile stimuli, resulting in respiratory problems associated
with asthma and chronic obstructive pulmonary disease (Pelaia et al., 2008).
However, cAMP regulates a number of other important cellular activities, including
carbohydrate and lipid metabolism, gene expression, as well as cell growth and
proliferation (Billington et al., 2013). In human ASM cells, cAMP production is linked
to the activation of β2 adrenergic receptors (β2ARs) as well as EP2 prostaglandin
receptors (EP2Rs) (Bogard et al., 2011). However, these receptors do not all produce
the same cAMP-dependent responses. For example, only β2AR activation leads to
enhanced arborization (Bogard et al., 2012), a cell shape change that reflects
cytoskeletal reorganization (Gros et al., 2006), while only EP2R activation increases
expression of the cytokine interleukin-6 (IL-6) (Bogard et al., 2014). This raises the
question as to how a cell is able to discriminate between cAMP signals that are
produced by these two types of receptors.
The current hypothesis is that β2ARs and EP2Rs produce cAMP in different
subcellular compartments. This is supported by the fact that these receptors are
found in different membrane domains (Ostrom et al., 2001). The plasma membrane
of most cells contains cholesterol and sphingomyelin rich areas referred to as lipid
rafts. In ASM cells, β2ARs are found in lipid raft fractions associated specifically with
caveolins, which are membrane bound scaffolding proteins that can contribute to the
formation of caveolae. EP2Rs, on the other hand, are excluded from lipid raft
fractions of the plasma membrane. Previous studies also indicate that different
cAMP dependent responses are associated with specific isoforms of adenylyl
cyclase (AC). ASM cells express multiple AC isoforms, including AC2 as well as AC6
(Xu et al., 2001; Bogard et al., 2011). Furthermore, AC6 is found specifically in lipid
raft fractions of the plasma membrane, while AC2 is excluded from these domains.
In addition, overexpression of AC6 enhances β2AR production of cAMP and cAMPdependent arborization in ASM cells (Bogard et al., 2012), whereas overexpression
of AC2 enhances EP2R production of cAMP as well as cAMP-dependent expression
of IL-6 (Bogard et al., 2014).
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The evidence described above is consistent with the idea that receptordependent production of cAMP is spatially restricted to subcellular locations
associated with different membrane microdomains. They also show that distinct AC
isoforms exist in these separate domains and couple specifically to co-localized
receptors. The purpose of this study was to directly test this hypothesis by
measuring cAMP activity in live, primary human ASM cells using the genetically
encoded FRET-based biosensor Epac2-camps targeted to different subcellular
locations. Epac2-camps consists of a cAMP binding domain from the type 2
exchange protein activated by cAMP, to which EYFP has been added to the Nterminus and ECFP to the C-terminus. Binding of cAMP causes a conformational
change resulting in a loss of energy transfer between the two fluorophores that can
be detected as an increase in the ECFP/EYFP fluorescence ratio. Epac2-camps
itself is a probe that lacks any targeting sequences, and was used to measure cAMP
responses in the bulk cytoplasmic compartment of the cell (Nikolaev et al., 2004).
Addition of either an acylation (Epac2-MyrPalm) or prenylation (Epac2-CAAX)
sequence was used to target the probe to lipid raft and non-lipid raft domains of the
plasma membrane, so that we could measure cAMP responses associated with
those subcellular locations (Agarwal et al., 2014). We also measured responses
using Epac2-NLS, which is targeted to the nucleus of the cell (DiPilato et al., 2004).
Our results demonstrate that stimulation of β2ARs and EP2Rs results in
production of cAMP in distinctly different subcellular locations in primary human ASM
cells. While β2ARs produce cAMP that is detected uniformly throughout all sites
examined, EP2Rs have the greatest effect on cAMP production in subcellular
locations associated with non-lipid raft domains of the plasma membrane as well as
the nucleus.

Methods
Cell Culture. Human ASM cells were provided by Dr. Raymond Penn (Thomas
Jefferson University). Cells were derived from human tracheae and primary bronchi
as previously described and used between passage 6 and 9 (Yan et al., 2011).
Experiments were conducted using multiple samples of primary cells derived from
different patients. Cells were maintained in Ham’s F12 nutrient mixture
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supplemented with 10% fetal bovine serum, 100 units/ml penicillin, 100 µg/ml
streptomycin. For FRET and confocal microscopy experiments, cells were plated on
35 mm glass-bottom fluorodishes (World Precision Instruments, Inc.). Cells were
transduced with adenovirus constructs containing Epac2-based cAMP biosensors for
48 hours. For AC overexpression experiments, adenoviral constructs expressing
AC2 were used to transduce cells; a viral titer previously shown to produce >90%
transduction was used (Bogard et al., 2011). All experiment were conducted at room
temperature.
FRET biosensor construction. The Epac2-camps, Epac2-MyrPalm, and
Epac2-CAAX biosensors used in the present study have been previously
characterized (Nikolaev et al., 2004; Agarwal et al., 2014). For nuclear targeting, a
nuclear localization signal (NLS), PKKKRKVEDA, was added to the C-terminus of
Epac2-camps probe (DiPilato et al., 2004). In vitro calibration of Epac2-NLS
(supplemental figure S1) was performed as described previously (Agarwal et al.,
2014). The EC50 and Hill coefficient for cAMP activation of each of the probes used
in this study are listed in supplemental table 1.
FRET microscopy. Live cell imaging experiments were conducted using
human ASM cells bathed in the following solution (in mM): NaCl 137, KCl 5.4, MgCl2
0.5, CaCl2 1.0, NaH2PO4 0.33, glucose 5.5, and HEPES 5 (pH 7.4). A plastic insert
(Warner Instruments) was used to reduce the total fluid volume of the fluorodish to
~200 µl, and drug containing solutions were introduced using a gravity fed perfusion
system at a rate of ~1 ml/min. FRET imaging was conducted using an Olympus IX71
inverted microscope equipped with an Hamamatsu OrcaD2 dual chip CCD camera
and HCImage data acquisition and analysis software (Hamamatsu Photonics, Ltd.),
as described previously (Agarwal et al., 2014). Changes in cAMP activity were
defined as the change in background and bleed-through corrected ECFP/EYFP
fluorescence intensity ratio (R) relative to the baseline ratio (R0) measured in a
specified region of interest. FRET ratios were measured once every 10 seconds. A
control period of at least 5 min was recorded prior to the application of any drug in
order to allow the baseline to stabilize. Responses were calculated relative to the
average baseline ratio measured over the 30 s period immediately preceding the
application of drugs.
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To control for variations in the absolute size of responses, these values were
then normalized to the magnitude of the maximal probe response observed in the
same cell following exposure to saturating concentrations of the non-specific PDE
inhibitor 3-isobutlyl-1-methylxanthine (IBMX) plus the direct AC activator forskolin or
the βAR agonist isoproterenol. For Epac2-camps, Epac2-MyrPalm, and
Epac2.CAAX, FRET responses were measured using a circular region of interest
(ROI) approximately 5 µm in diameter placed over a cytoplasmic region of the cell,
being sure to avoid the nucleus. Consistent with the results of Billington et al. (2008),
results obtained using ROIs placed at different locations did not affect the results.
For cells expressing Epac2-NLS, the ROI was drawn around the entire nucleus.
Confocal microscopy. Confocal imaging was performed using an Olympus
Fluoview 1000 confocal microscope with an oil immersion objective (60x, 1.42 NA).
The confocal aperture was fixed at 1 Airy unit. Images were captured at 1024 x 1024
pixels with a 20 µs/pixel dwell time and 2x zoom in raster scan mode using a laser
power of 5-10%. EYFP in cells expressing the different biosensors was excited using
the 515 nm line of an argon laser and the fluorescence images were captured using
a BA535-565 emission filter. Images were stored in tiff file format. The brightness
and contrast of these images were adjusted in ImageJ software for presentation
purposes.
Materials. Rolipram was obtained from Tocris Bioscience. Ham’s F12
medium, penicillin, streptomycin, and fetal bovine serum were purchased from Life
Technologies. All other reagents were purchased from Sigma-Aldrich. Isoproterenol
and IBMX containing solutions were prepared fresh daily. Forskolin and butaprost
containing solutions were prepared from frozen aliquots.
Statistics. All data are expressed as the mean ± SEM of the indicated number
of experiments conducted using individual cells (n). Statistical significance (p < 0.05)
was determined by Student’s t-test or one way ANOVA with Holm-Sidak post-hoc
analysis to identify significant outliers, where appropriate, using SigmaPlot (Systat
Software, Inc.).

Nomenclature of Targets and Ligands. Key protein targets and ligands in this
article are hyperlinked to corresponding entries in
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http://www.guidetopharmacology.org, the common portal for data from the
IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016), and are
permanently archived in the Concise Guide to PHARMACOLOGY 2015/16
(Alexander et al., 2015a; Alexander et al., 2015b).

Results
In order to monitor changes in cAMP levels associated with specific subcellular
locations, we employed genetically-encoded Epac2-based biosensors with or without
different targeting sequences (DiPilato et al., 2004; Agarwal et al., 2014). When
expressed in human ASM cells, we observed distinct patterns of expression for each
of these probes (figure 1A). As expected, Epac2-camps, the probe without any
targeting sequence, exhibited diffuse fluorescence throughout the cytosol. Epac2MyrPalm and Epac2-CAAX, which are targeted to lipid raft and non-raft membrane
domains, respectively (Zacharias et al., 2002; Agarwal et al., 2014), were found
primarily in the plasma membrane. However, these two probes exhibited distinctly
different expression patterns. Wide field images of Epac2-MyrPalm expressing cells
revealed that this probe is expressed uniformly throughout the surface membrane of
these cells. However, the Epac2-CAAX probe appears to be concentrated more
around the nucleus, suggesting an association between non-raft domains of the
plasma membrane and the perinuclear space (figure 1B, left hand panels). In cells
expressing Epac2-NLS, a highly localized nuclear fluorescence pattern was distinctly
visible. These results indicate that each of our cAMP biosensors is targeted to a
distinctly different subcellular location.
Next, we conducted experiments to verify that these probes were able to
respond to changes in cAMP levels. Exposure to forskolin (10 µM), to directly
activate AC activity, in combination with IBMX (100 µM), a non-specific inhibitor of
phosphodiesterase (PDE) activity, was used to produce a saturating cAMP
response. Comparing the left and right hand panels of figure 1B, there was no
obvious change in the distribution pattern of the probes following stimulation.
However, the change in activity was readily detectible as a change in the
ECFP/EYFP fluorescence ratio illustrated as pseudocolor images in figure 1C.
Interestingly, the time course experiments illustrated in figure 2 demonstrate that
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exposure to 100 µM IBMX alone, a concentration that should maximally inhibit most
PDE isoforms, produced responses that were only 16 to 26% of that observed
following maximal activation of each probe upon subsequent addition of 10 µM
forskolin. These results suggest that under basal conditions, total PDE activity is
similar in all four locations. They also suggest that basal AC activity in these
locations is low. Consistent with this conclusion, exposure to 100 µM MDL-12,330A,
an AC inhibitor, did not produce a significant decrease in the baseline FRET
responses detected by any of our probes (see supplemental figure 2). This suggests
that basal levels of cAMP are below the threshold for detection by our probes
(Agarwal et al., 2014).
To determine if there are differences in the relative amount of AC activity
capable of contributing to cAMP production in different subcellular locations upon
stimulation, we examined the concentration dependence of the responses to
forskolin (figure 3). While all four probes responded to forskolin in a concentrationdependent manner, there were differences in the apparent sensitivity. Exposure to
0.1 µM forskolin produced responses that could be detected by every probe except
Epac2-MyrPalm. Exposure to 0.3 µM forskolin produced responses that could be
detected by all four probes, although Epac2-CAAX and Epac2-NLS appeared to be
the most sensitive. Exposure to 10 µM forskolin produced responses that resulted in
saturation or near saturation of all four probes. These results indicate that even
though basal AC activity appears to be low, agonist stimulated AC activity is quite
significant. However, there appear to be some differences in the relative amount of
AC activity contributing to cAMP production in different subcellular locations.
We next compared responses to G protein coupled receptor (GPCR)
activation. Exposure to the βAR agonist isoproterenol produced concentration
dependent increases in cAMP activity throughout the cell (figure 4), without any
apparent differences in the sensitivity of the responses detected by each of the
probes. Exposure to 1 nM isoproterenol produced responses that were 22 to 42% of
maximal, while 3 nM isoproterenol produced responses that were between 55 and
82% of maximal. Exposure to a maximally stimulating concentration of isoproterenol
(1 µM) produced responses that were approximately the same size as those
observed in the presence of 1 µM isoproterenol plus 100 µM IBMX. These results
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suggest that β2AR stimulation produces cAMP levels that are roughly equal
throughout human ASM cells.
Contrary to the effects of β2AR stimulation, exposure to the EP2R agonist
butaprost produced a significantly different pattern of responses (figure 5). Exposure
to 0.3 and 1 µM butaprost produced concentration dependent increases in cAMP
activity detected by the Epac2-CAAX and Epac2-NLS biosensors. In sharp contrast,
the cytosolic biosensor Epac2-camps responded to 1 µM but not 0.3 µM butaprost,
and the lipid raft targeted probe Epac2-MyrPalm did not respond to either
concentration of butaprost. These results suggest that EP2R stimulation elicits a
localized increase in cAMP activity in subcellular locations associated with non-raft
regions of the plasma membrane. Furthermore, while the cAMP produced by theses
receptors is unable to reach the subcellular locations associated with lipid rafts, it is
readily able to reach the nucleus.
It has previously been shown that inhibition of type 4 PDE activity (PDE4)
enables EP2R stimulation to cause arborization of ASM cells (Bogard et al., 2012).
This suggests that PDE4 is involved in limiting the spread of cAMP produced by
EP2Rs. To test this hypothesis, we examined the effect of the selective PDE4
inhibitor rolipram on the cAMP responses produced by butaprost (figure 6).
Exposure to 10 µM rolipram alone had no significant effect on cAMP activity detected
by any of the probes. However, the presence of rolipram did alter the response to 1
µM butaprost, eliminating any significant difference in the magnitude of the
responses detected by any of the probes. Most notable was the fact that the Epac2MyrPalm probe was able to detect a change in cAMP activity following exposure to 1
µM butaprost. This is in contrast to the absence of any change in cAMP activity
detected by this probe when butaprost was applied in the absence of rolipram (see
figure 5).
Previous studies have suggested that EP2Rs couple specifically to AC2 in
non-raft regions of the plasma membrane in ASM cells (Bogard et al., 2011; Bogard
et al., 2012; Bogard et al., 2014). To examine this possibility, we compared the
cAMP responses detected by the lipid raft targeted Epac2-MyrPalm and non-raft
targeted Epac2-CAAX probes in ASM overexpressing AC2 (figure 7). The results
demonstrate that AC2 overexpression had no effect on the inability of butaprost to
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elicit a response detected by Epac2-MyrPalm. However, AC2 overexpression did
significantly enhance the response to 1 µM butaprost detected by Epac2-CAAX
(figure 7D). To verify that this result was specific for EP2R activation, we also
examined the effect of AC2 overexpression on the responses to β 2AR stimulation
(figure 8). The results demonstrate the AC2 overexpression did not enhance the
responses to isoproterenol detected by either Epac2-MyrPalm or Epac2-CAAX. If
anything, the responses to isoproterenol measured by both of these probes were
slightly decreased.

Discussion
Human ASM cells, like most cell types, express several GPCRs linked to the
production of cAMP. A long-standing quandary is how these receptors, which
respond to a vast array of neurohumoral signals, yield different cellular responses via
the same second messenger. The results of the present study demonstrate that the
segregation of signaling proteins into different membrane domains plays an
important role in generating spatially localized cAMP production in human ASM cells
(Bogard et al., 2011; Bogard et al., 2012; Ostrom et al., 2012; Bogard et al., 2014).
Specifically, our results support the conclusion that EP2R activation of AC2
generates a localized pool of cAMP in subcellular locations associated with non-lipid
raft domains of the plasma membrane. This is based on two primary observations.
First, EP2R stimulation causes a rise in cAMP levels that are detected by the non-raft
targeted Epac2-CAAX biosensor, but not the raft-anchored Epac2-MyrPalm probe
(see figure 5). Second, overexpression of AC2 augments EP2R stimulation of cAMP
in non-raft domains, but not lipid raft associated domains (see figure 7), without
enhancing β2AR responses in either location (see figure 8). These data indicate that
EP2R and β2AR exist in distinct microdomains and couple selectively to different AC
isoforms, consistent with previous findings (Bogard et al., 2011; Bogard et al., 2012).
Previous reports indicate that activation of AC2 regulates the production of IL6 in ASM cells (Bogard et al., 2014). IL-6 gene expression involves protein kinase A
(PKA) activation of the cAMP response element binding protein (CREB), and
subsequent enhancement of gene transcription (Yamamoto et al., 1988). It is
believed that the binding of cAMP to PKA releases the catalytic subunit of the
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kinase, allowing it to translocate from cytoplasm into the nucleus where it
phosphorylates CREB (Harootunian et al., 1993; Altarejos & Montminy, 2011). If this
is the case, then activation of PKA anywhere in the cell might be expected to equally
regulate all CRE-containing gene promoters. However, the fact that AC6-derived
cAMP production does not affect the expression of IL-6, and AC2-derived cAMP
production does not increase expression of somatostatin, another CRE-regulated
gene (Bogard et al., 2014), suggests that this is not the case. It implies that the
subcellular location of cAMP production is important for how the nucleus interprets
such signals. Consistent with this idea, EP2R stimulation was also able to produce
significant changes in cAMP that could be detected by our nuclear targeted
biosensor Epac2-NLS. In fact, EP2R stimulation produced changes in cAMP at the
nucleus that appeared to be greater than those detected near the plasma membrane
by Epac2-CAAX (see figure 5). The explanation for this difference is not immediately
obvious, but may be due to EP2Rs being expressed in nuclear membranes. It is
interesting to note that the probe targeted to non-lipid raft domains of the plasma
membrane appears to concentrate around the nucleus (see figure 1B).
β2AR activation was also able to produce changes in cAMP that were
detected by the nuclear probe, indicating that signals emanating from lipid raft
domains are able to reach the nucleus as well. Thus, a complex model of how cAMP
signals convey information to the nucleus is needed. It may be that cAMP signals
originating from different locations activate different arrays of PKA phosphorylated
signaling proteins, such that the resulting information flowing to the nucleus is unique
for each locale. Future studies are needed to determine whether the subcellular
pattern of PKA activation correlates directly with that of cAMP production. A kinase
anchoring proteins (AKAPs) could fulfill some of the role in targeting PKA action in
specific signaling complexes. AKAPs shape β2AR responses in human ASMs by
regulating receptor and PDE phosphorylation to create negative feedback (Horvat et
al., 2012; Ostrom et al., 2012). Different AKAPs bind specific AC isoforms, creating
the likelihood that these proteins organize downstream elements into signaling
complexes (Efendiev & Dessauer, 2011).
It has also been reported that cAMP produced by the EP2R and AC2 in nonraft domains are not able to regulate ASM cell arborization (a response robustly
enhanced by β2AR and AC6) unless a PDE4 inhibitor is added (Bogard et al., 2012).
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Again, differences in the subcellular location of cAMP production are likely to be
involved in explaining these observations. The present results demonstrate that
β2AR stimulation was able to increase cAMP to similar levels in all locations
examined (see figure 4). By contrast, EP2Rs failed to produce a detectable change in
cAMP in locations associated with lipid raft domains of the plasma membrane and
more weakly produced cAMP detected by the cytosolic sensor (figure 5). Because
the non-raft targeted probe was concentrated centrally, in the membrane around the
nucleus, whereas the lipid-raft targeted probe was found more uniformly throughout
the plasma membrane, it is conceivable that cAMP produced in the periphery of the
cell may be more important in regulating cell shape. IBMX did not have drastically
different effects on cAMP levels detected by the Epac2-CAAX sensor. However,
overexpression of AC2 increased cAMP signaling in the non-raft domain but did not
produce “spillover” into the lipid raft domain (as sensed by Epac2-MyrPalm), implying
that cAMP diffusion from the EP2R-AC2 complex in the non-raft domain is more
restricted.
Phosphodiesterase activity is thought to play an essential role in
compartmentation of cAMP responses, and PDE4 is believed to be the predominant
isoform regulating cAMP activity in human ASM cells (Conti et al., 2003; Houslay &
Adams, 2003; Méhats et al., 2003; Billington et al., 2008; Nino et al., 2009; Xin et al.,
2015). In fact, previous studies found that inhibition of PDE4 unmasks the ability of
AC2-mediated cAMP production to cause arborization of ASM cells (Bogard et al.,
2012). Consistent with this observation, we found that inhibition of PDE4 activity was
also able to significantly increase the diffusion of EP2R mediated cAMP production.
Most notable was the fact that inhibition of PDE4 revealed a cAMP response
previously undetectable by Epac2-MyrPalm in subcellular locations associated with
lipid rafts (see figure 6). This could be explained if PDE4 activity is more
concentrated in subcellular locations associated with lipid rafts, limiting the ability of
cAMP produced in non-raft domains from diffusing in and reaching significant levels.
If true, then the increase in PDE4D activity that occurs with asthma (Trian et al.,
2011) might be expected to limit cAMP signaling associated specifically with these
microdomains.
It is worth noting, however, that IBMX, which inhibits most PDE isoforms,
produced a small, but significant change in basal cAMP activity in all subcellular

This article is protected by copyright. All rights reserved.

locations (see figure 2). This indicates that all microdomains contain some PDE
activity. However, if IBMX had inhibited all PDE activity, we would have expected to
see saturating responses. The fact that we did not suggests that there must be some
IBMX-insensitive PDE activity in these cells. Furthermore, because inhibition of
PDE4 activity alone had no significant effect (see figure 6), this suggests that human
ASM cells also express IBMX-sensitive PDE isoforms other than just PDE4.
Modeling studies have also suggested that while PDE activity is essential, it alone
cannot explain cAMP compartmentation (Saucerman et al., 2014). In addition to
segregation of receptors and ACs in distinct physical locations, other contributing
factors are likely to include slow diffusion of cAMP that is independent of PDE
activity (Agarwal et al., 2016) as well as restricted spaces defined by cell morphology
(Feinstein et al., 2012; Yang et al., 2016). As a result, once cAMP is produced by a
particular AC isoform in a specific location, that signal is not freely diffusible so these
distinct signals can regulate different downstream responses by the cell.
Smooth muscle cells can undergo phenotypic changes with time in culture.
However, it has been reported that cAMP responses are maintained in human ASM
cells well beyond the passage number used in the present study (Stewart et al.,
1997). Furthermore, the receptor specific cAMP responses we observed are
consistent with previous results obtained using similar cells (Bogard et al., 2011;
Bogard et al., 2012; Bogard et al., 2014).
In conclusion, our study provides the first direct evidence for the generation of
receptor-mediated production of spatially localized pools of cAMP within different
microdomains of primary human ASM cells. EP2R-stimulated cAMP signaling is
clearly more restricted than β2AR-stimulated cAMP signaling in near-membrane
regions even though both receptors elicit cAMP signaling at the nucleus. The results
add to our understanding of how this common second messenger may elicit distinct
receptor-specific functional responses in these cells.
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Figure 1. Expression pattern of Epac2-based biosensors targeted to different
subcellular locations. (A) Representative confocal images of human ASM cells
expressing Epac2-MyrPalm (MyrPalm, n = 27), Epac2-CAAX (CAAX, n = 68),
Epac2-NLS (NLS, n = 25), and Epac2-camps (Epac2, n = 18). (B) Representative
wide field images (EYFP fluorescence) before (left) and after (right) stimulation of
cAMP production by exposure to the adenylyl cyclase activator forskolin (FSK, 10
µM) plus the phosphodiesterase inhibitor IBMX (100 µM). Note, there is no obvious
change in distribution of biosensor following stimulation of cAMP production. (C)
Corresponding pseudocolor images depicting the change in ECFP/EYFP
fluorescence intensity ratio before (left) and after (right) exposure to FSK plus IBMX.
MyrPalm (n = 6), CAAX (n = 6), NLS (n = 9) and Epac2 (n = 8)
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Figure 2. Changes in cAMP responses in different subcellular domains
following phosphodiesterase inhibition. (A-D) Representative time course of
changes in the magnitude of the normalized FRET response (R/R0) in human
airway smooth muscle cells expressing Epac2-MyrPalm (MyrPalm), Epac2-CAAX
(CAAX), Epac2-NLS (NLS), and Epac2-camps (Epac2), under control conditions,
This article is protected by copyright. All rights reserved.

following exposure to 100 μM IBMX, and IBMX plus 10 µM forskolin (FSK). (E) Size
of average FRET responses to 100 µM IBMX alone normalized to the magnitude of
the maximal response measured in the presence of IBMX plus FSK. There was no
statistical difference (p < 0.5, One Way ANOVA) in the size of the responses
detected by MyrPalm (16 ± 6.4%, n = 6), CAAX (21 ± 5.9%, n = 6), NLS (26 ± 3.0%,
n = 9), and Epac2 (20 ± 1.1%, n = 8).
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Figure 3. Changes in cAMP responses in different subcellular domains
following adenylyl cyclase activation. (A-D) Representative time course of
changes in the magnitude of the normalized FRET response (R/R0) in cells
expressing Epac2-MyrPalm (MyrPalm), Epac2-CAAX (CAAX), Epac2-NLS (NLS),
and Epac2-camps (Epac2), under control conditions, and following exposure to 0.1
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µM, 0.3 µM, and 10 µM forskolin (FSK). (E) Size of average FRET responses to
FSK. The 0.1 µM FSK response detected by MyrPalm (0.33 ± 5.4%, n = 6) was
significantly smaller (p = 0.032) than that detected by CAAX (31 ± 10%, n = 6), but
not NLS (16 ± 6.3%, n = 6) and Epac2 (14 ± 4.9%, n = 8). The 0.3 µM FSK
responses detected by MyrPalm (28 ± 8.6%, n = 6) and Epac2 (48 ± 3.8%, n = 7)
were significantly smaller (p < 0.01) than those detected by CAAX (66 ± 13%, n = 6)
and NLS (71 ± 3.6%, n = 14). The 10 µM FSK responses detected by CAAX (100 ±
1.8%, n=5), MyrPalm (92 ± 5.0, n = 6), NLS (85 ± 2.3, n=13), and Epac2 (93 ±1.3,
n=6), were not significantly different from one another (p > 0.05). Statistical
significance was tested using One Way ANOVA followed by Holm-Sidak method for
pairwise multiple comparisons. All responses were normalized to the maximal
responses elicited by 10 µM FSK plus 100 µM IBMX.
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Figure 4. Changes in cAMP responses in different subcellular domains
following β-adrenergic receptor stimulation. (A-D) Representative time course of
changes in the magnitude of the normalized FRET response (R/R0) in cells
expressing Epac2-MyrPalm (MyrPalm), Epac2-CAAX (CAAX), Epac2-NLS (NLS),
and Epac2-camps (Epac2), under control conditions, and following exposure to 1
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nM, 3 nM, and 1 µM isoproterenol (Iso). (E) Size of average FRET responses to Iso.
1 nM Iso: MyrPalm, 22 ± 5.4% (n = 13); CAAX, 25 ± 8.2% (n = 9); NLS, 42 ± 14% (n
= 7); and Epac2, 29 ± 8.3% (n = 7). 3 nM Iso: MyrPalm, 55 ± 7.0% (n = 13), CAAX,
57 ± 9.4% (n = 9); NLS, 82 ± 13% (n = 7); and Epac2, 59 ± 3.9% (n = 7). 1 µM Iso:
MyrPalm, 96 ± 4.5% (n = 18); CAAX, 98 ± 5.5% (n = 19); NLS, 102 ± 6.8% (n = 15);
and Epac2, 84 ± 5.2% (n = 11). There were no significant differences (p > 0.05, One
Way ANOVA) in the size of the responses to any given concentration of Iso. All
responses were normalized to the maximal responses elicited by 1 µM Iso plus 100
µM IBMX.
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Figure 5. Changes in cAMP responses in different subcellular domains
following E-type prostaglandin receptor stimulation. (A-D) Representative time
course of changes in the magnitude of the normalized FRET response (R/R0) in
cells expressing Epac2-MyrPalm (MyrPalm), Epac2-CAAX (CAAX), Epac2-NLS
(NLS), and Epac2-camps (Epac2), under control conditions, and following exposure
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to 0.3 µM and 1 µM butaprost (But). (E) Size of average FRET responses to But.
The responses to 0.3 µM But detected by MyrPalm (-0.30 ± 2.5%, n = 11) and Epac2
(1.27 ± 4.1%, n = 8) were significantly smaller (p < 0.05) than those detected by
CAAX (15 ± 4.0%, n = 12) and NLS (26 ± 4.0%, n = 7). The response to 1 µM But
detected by MyrPalm (2.3 ± 4.5%, n = 11) was significantly smaller (p < 0.05) than
the responses detected by CAAX (24 ± 5.7%, n = 10), NLS (43 ± 4.7%, n = 7), and
Epac2 (16 ± 7.0%, n = 8). The Epac2 response was also significantly smaller than
the NLS response (p < 0.05). Statistical significance was tested using One Way
ANOVA followed by Holm-Sidak method for pairwise multiple comparisons. All
responses were normalized to the maximal responses elicited by 10 µM FSK plus
100 µM IBMX.
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Figure 6. Effect of phosphodiesterase 4 (PDE4) inhibition on cAMP responses
elicited by E-type prostaglandin receptor stimulation. Representative time
course of changes in the magnitude of the FRET response (R/R0) in cells
expressing Epac2-MyrPalm (MyrPalm), following exposure to 1 µM butaprost (But) in
the absence (A) or presence (B) of the PDE4 inhibitor rolipram (Rol, 10 µM). (C)
Size of average FRET responses to 10 µM Rol or Rol plus 1 µM But. There were no
significant differences (p > 0.05) in the size of the responses to 1 µM Rol detected by
MyrPalm (-6.2 ± 4.2%, n = 10), Epac2-CAAX (CAAX; 8.9 ± 4.9%, n = 8), Epac2-NLS
(NLS; 2.9 ± 2.2 %, n = 6); and Epac2-camps (Epac2; 0.61 ± 2.3%, n = 5). There
were also no significant differences in the size of the responses to 1 µM But in the
presence of 10 µM Rol detected by MyrPalm (27 ± 14%, n = 7), CAAX (36 ± 8.3%, n
= 8), NLS (66 ± 5.4%, n = 6), and Epac2 (34 ± 12%, n = 5). Statistical significance
was tested using One Way ANOVA. All responses were normalized to the maximal
response elicited by 10 µM forskolin (FSK) plus 100 µM IBMX.
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Figure 7. Effect of adenylyl cyclase 2 (AC2) overexpression on cAMP
responses elicited by E-type prostaglandin receptor stimulation. Representative
time course of changes in the normalized FRET response (R/R0) detected by
Epac2-MyrPalm (MyrPalm) (A) and Epac2-CAAX (CAAX) (B) following exposure to
0.3 µM and 1 µM butaprost (But) in cells overexpressing AC2. (C) Size of average
FRET responses in AC2 overexpressing (AC2 OE) cells. The size of the response to
0.3 µM butaprost detected by MyrPalm (-0.81 ± 0.73%, n = 5) was significantly
smaller (p < 0.05) than that detected by CAAX (16 ± 5.2%, n = 9). The size of the
response to 1 µM butaprost detected by MyrPalm (3.3 ± 5.7%, n = 3) was also
significantly smaller (p < 0.05) than that detected by CAAX (48 ± 9.5%, n = 9). (D)
Difference in magnitude of butaprost responses due to AC2-overexpression. 0.3 µM
butaprost responses: MyrPalm, -0.51 ± 2.5 (n = 11); CAAX, 1.0 ± 4.0 (n = 12). 1 µM
butaprost responses: MyrPalm, 1.0 ± 4.5 (n = 11); CAAX, 24 ± 5.7 (n = 10). The
effect of AC2 overexpression on the response to 1µM butaprost detected by CAAX
was significantly greater than that detected by MyrPalm (p < 0.05). Statistical
significance was tested using One Way ANOVA followed by Holm-Sidak method for
pairwise multiple comparisons. All responses were normalized to the maximal
response elicited by 10 µM forskolin (FSK) plus 100 µM IBMX.
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Figure 8. Effect of adenylyl cyclase 2 (AC2) overexpression on cAMP
responses elicited by β-adrenergic receptor stimulation. Representative time
course of changes in the normalized FRET response (R/R0) detected by Epac2MyrPalm (MyrPalm) (A) and Epac2-CAAX (CAAX) (B), following exposure to 1 nM
and 3 nM isoproterenol (Iso) in cells overexpressing AC2. C Size of average FRET
responses in AC2 overexpressing cells. 1 nM Iso: MyrPalm, 16 ± 5.9% (n = 5);
CAAX, 11 ± 3.6% (n = 3). 3 nM Iso: MyrPalm, 33 ± 9.3% (n = 5); CAAX, 42 ± 10% (n
= 3). D Difference in magnitude of Iso responses due to AC2 overexpression. 1 nM
Iso: MyrPalm, -6.7 ± 5.4 (n = 13); CAAX, -10 ± 7.1 (n = 11). 3 nM Iso: MyrPalm, -22 ±
7.0 (n = 13); CAAX, -5.1 ± 9.9 (n = 11). There was no significant difference in the
effects of AC2 overexpression on the responses detected by the different biosensors
(p < 0.05, One Way ANOVA). All responses were normalized to the maximal
response elicited by 1 µM Iso plus 100 µM IBMX.
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Figure 9. Compartmentalized cAMP signaling in human airway smooth muscle
cells. EP2 prostaglandin receptor (EP2R) stimulation of adenylyl cyclase type 2
(AC2) in non-lipid raft domains of the plasma membrane produces cAMP that can be
detected by Epac2-CAAX, Epac2-NLS, and Epac2-camps biosensors. β2 adrenergic
receptor (β2AR) stimulation of adenylyl cyclase type 6 (AC6) in lipid raft domains of
the plasma membrane produces cAMP that can be detected by Epac2-MyrPalm,
Epac2-camps, Epac2-NLS, as well as Epac2-CAAX biosensors.
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